Gerd Ritter
59Patents
12h-index
82Co-inventors
87Inventor score
Filing activity: Oct 18, 1988 → Mar 21, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6342587B1 | A33 antigen specific immunoglobulin products and uses thereof | Chemistry; Metallurgy | 73 | Expired |
| US5712369A | Isolated protein which binds to A33 antibody, and peptides corresponding to portions of the protein | Chemistry; Metallurgy | 48 | Expired |
| US7589180B2 | Specific binding proteins and uses thereof | Chemistry; Metallurgy | 37 | Expired |
| US5851526A | Methods of treating colon cancer utilizing tumor-specific antibodies | Chemistry; Metallurgy | 24 | Expired |
| US5102663A | Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3 | Emerging Cross-Sectional Technologies | 24 | Expired |
| US6652853B2 | Method for treating cancer using A33 specific antibodies and chemotherapeutic agents | Chemistry; Metallurgy | 17 | Expired |
| US6190640A | Method for treating neoplasia using humanized antibodies which bind to antigen A33 | Chemistry; Metallurgy | 16 | Expired |
| US6291235A | Isolated nucleic acid which encodes protein which binds to A33 antibody | Chemistry; Metallurgy | 16 | Expired |
| US10280226B2 | Anti-GITR antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 14 | Active |
| US10155818B2 | Anti-GITR antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 14 | Active |
| US6057115A | Process for producing GM2 specific antibodies | Physics | 13 | Expired |
| US8603474B2 | Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy | Physics | 12 | Active |
| US10259882B2 | Anti-OX40 antibodies | Physics | 11 | Active |
| US10836830B2 | Antibodies and methods of use thereof | Chemistry; Metallurgy | 9 | Active |
| US6723832B1 | Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof | Human Necessities | 6 | Expired |
| US6346249B1 | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products | Chemistry; Metallurgy | 6 | Expired |
| US9072798B2 | Specific binding proteins and uses thereof | Chemistry; Metallurgy | 6 | Active |
| US10626181B2 | Nucleic acids encoding anti-OX40 antibodies | Physics | 5 | Active |
| US10144779B2 | Anti-CTLA-4 antibodies and methods of use thereof | Chemistry; Metallurgy | 5 | Active |
| US10479833B2 | Anti-CTLA-4 antibodies and methods of use thereof | Chemistry; Metallurgy | 4 | Active |
| US10912831B1 | Anti-CTLA-4 antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 4 | Active |
| US9045533B2 | Membrane transporter NaPi2b (SCL34A2) epitope antibodies | Physics | 3 | Active |
| US11013802B2 | Anti-CTLA-4 antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US10323091B2 | Anti-PD-1 antibodies and methods of use thereof | Chemistry; Metallurgy | 3 | Active |
| US10577426B2 | Anti-GITR antibodies and methods of use thereof | Emerging Cross-Sectional Technologies | 3 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.